Department of Ophthalmology, University of Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Germany.
Ophthalmological Center Lippstadt, Wiedenbrücker Str. 31, 59555, Lippstadt, Germany.
J Neural Transm (Vienna). 2021 Jun;128(6):793-802. doi: 10.1007/s00702-021-02343-x. Epub 2021 May 8.
Validation of the new hemifacial spasm (HFS) questionnaire "HFS score" that captures both clinical (HFS clinical) and health-related quality of life (HRQOL) parameters (HFS subjective) in one tool and comparison with a global HRQOL questionnaire. Cross sectional, prospective validation study including 143 subjects (62 HFS patients and 81 healthy volunteers) from the University Eye Hospital Bonn. Patients were interviewed with the new HFS score and the SF-12 questionnaire prior to and 3 weeks after Botulinum neurotoxin A (BoNT-A) injection. All HRQOL-related questions (HFS subjective) were answered on a visual analogue scale (VAS) ranging from 0 (no complaints) to 100% (maximum complaints) by the patients themselves. Reproducibility was tested in a study extension with 10 patients by repeat interviews (telephone/personal). The new HFS score questionnaire provided a reliable clinical assessment and demonstrated that BoNT-A therapy significantly reduced frequency and severity of eye and cheek spasms (p < 0.001; Wilcoxon test). Relevant aspects of HRQOL of HFS patients were assessed with high accuracy and sensitivity. Significant improvements were achieved after BoNT-A injection in five out of eight HRQOL parameters (p ≤ 0.02; Wilcoxon test). Cronbach's alpha of 0.818 demonstrated good internal consistency. Telephone survey provided comparable results to personal interviews. This new sensitive and specific HFS score seems a reliable instrument to monitor BoNT therapy and customize it to the needs of the individual HFS patient-in clinical studies and daily clinical practice.
新的面肌痉挛（HFS）问卷“HFS 评分”的验证，该问卷在一个工具中同时捕捉临床（HFS 临床）和与健康相关的生活质量（HRQOL）参数（HFS 主观），并与全球 HRQOL 问卷进行比较。横断面、前瞻性验证研究包括来自波恩大学眼科医院的 143 名受试者（62 名 HFS 患者和 81 名健康志愿者）。患者在肉毒杆菌毒素 A（BoNT-A）注射前和 3 周后分别用新的 HFS 评分和 SF-12 问卷进行访谈。所有与 HRQOL 相关的问题（HFS 主观）均由患者本人在视觉模拟量表（VAS）上回答，范围从 0（无投诉）到 100%（最大投诉）。在一项 10 名患者的研究扩展中，通过重复访谈（电话/个人）测试了可重复性。新的 HFS 评分问卷提供了可靠的临床评估，并表明 BoNT-A 治疗显著降低了眼部和脸颊痉挛的频率和严重程度（p<0.001；Wilcoxon 检验）。HFS 患者的 HRQOL 相关方面具有高度准确性和敏感性。BoNT-A 注射后，有 5 项 HRQOL 参数显著改善（p≤0.02；Wilcoxon 检验）。0.818 的 Cronbach's alpha 表明良好的内部一致性。电话调查提供了与个人访谈相当的结果。这种新的敏感和特异的 HFS 评分似乎是一种可靠的工具，可以监测 BoNT 治疗，并根据个体 HFS 患者的需求进行定制——在临床研究和日常临床实践中。
